Results after treatment with sildenafil citrate in 100 patients with erectile dysfunction
Abstract
OBJECTIVE: In order to know the efficiency, tolerance and acceptance of Sildenafil Citrate in our area as a new treatment for Eréctil Dysfunction (E.D.).
MATERIAL AND METHODS: We include 100 patients with E.D. who were assisted in our medical office from November 1998 to February 2000 to evaluate them according to several predeterminated variables.
RESULTS: The positive response index (E.D. improvement) was 69.9%. We only found side effects in 11.8% (headache 5.4%, flushing 4.3%, diarrhea/blurred vision 2.2%). The most widely used dose was 50 mgrs (65.6%). Only 50.5% of the patients had enough information about Sildenafil. The highest positive response index corresponded to the mild E.D. (76.1%). Also the best results were achieved with the mixed and psychological etiology (74.1%). The Sildenafil treatment was rejected (fear or its price) by the 46.2% of the patients.
CONCLUSIONS: The Sildenafil Citrate is an effective treatment for the E.D. It hardly has any side effects. The 50 mgrs dose got the best results. Almost half of the patients complained about an insufficient information on this pharmaceutical. Sildenafil got a good response even when there were risk associated factors of E.D.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 100 participants or records.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.